Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: Prognostic factors and outcome

Cerebrovascular Diseases

Volumn 31, Issue 3, 2011, Pages 278-283

  MacHumpurath, Bejoy ^a   Davis, Stephen M ^a   Yan, Bernard ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Recovery; Stroke; Tissue plasminogen activator

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VICTORIA; YOUNG ADULT;

EID: 78650239725     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322564     Document Type: Article

References (27)

1. Wolfe C, Rudd T: The Burden of Stroke White Paper. SAFE: Stroke Alliance For Europe. London, Stroke Association, 2007.
2. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-1276. (Pubitemid 27192468)
3. Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, Mc- Dermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie- Rosett J, Hong Y: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486.
4. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. New Engl J Med 1995; 333: 1581-1587.
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The Atlantis Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
7. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
8. Lindsberg PJ, Kaste M: Thrombolysis for acute stroke. Curr Opin Neurol 2003; 16: 73-80. (Pubitemid 36206765)
9. Schellinger PD, Kaste M, Hacke W: An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 2004; 17: 69-77. (Pubitemid 38316782)
10. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-870. (Pubitemid 19188240)
11. Christoforidis GA, Mohammad Y, Yang M, Caragine LP, Slivka A: Factors associated with a 'Lazarus phenomenon' 24 hours following intraarterial thrombolytic therapy in acute ischemic stroke. International Stroke Conference, San Francisco, 2007, p 507.
12. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
13. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UKTIA Study Group. Br Med J (Clin Res Ed) 1988; 296: 316-320.
14. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
15. Trouillas P, von Kummer R: Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006; 37: 556-561. (Pubitemid 43732026)
16. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282. (Pubitemid 46138121)
17. Fischer U, Arnold M, Nedeltchev K, Brekenfeld C, Ballinari P, Remonda L, Schroth G, Mattle HP: NIHSS score and arteriographic findings in acute ischemic stroke. Stroke 2005; 36: 2121-2125. (Pubitemid 41429231)
18. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
19. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP: Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.
20. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD: Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 2009; 32: 617-622.
21. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J: Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004; 35: 151-156. (Pubitemid 38057610)
22. de Silva DA, Ebinger M, Christensen S, Parsons MW, Levi C, Butcher K, Barber PA, Bladin C, Donnan GA, Davis SM: Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial. Cerebrovasc Dis 2010; 29: 14-21.
23. Huber K: Plasminogen activator inhibitor type-1. Part 1. Basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11: 183-193. (Pubitemid 33069415)
24. Schneider DJ, Nordt TK, Sobel BE: Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1-7. (Pubitemid 23013788)
25. Nicholls SC, Hoffer EK, Chandler WL: Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1. Blood Coagul Fibrinolysis 2003; 14: 729-733.
26. Zhu Y, Carmeliet P, Fay WP: Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055. (Pubitemid 29270436)
27. Zangerle A, Kiechl S, Spiegel M, Furtner M, Knoflach M, Werner P, Mair A, Wille G, Schmidauer C, Gautsch K, Gotwald T, Felber S, Poewe W, Willeit J: Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 2007; 68: 39-44. (Pubitemid 46058549)